Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival
Metrics: PDF 1378 views | HTML 1246 views | ?
Li-Ru He1,2, Ning-Fang Ma4, Jie-Wei Chen1,3, Bin-Kui Li1, Xin-Yuan Guan1,5, Meng-Zhong Liu1,2, Dan Xie1,3
1The State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
2Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
3Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China
4Department of Histology and Embryology, State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, China
5Departments of Clinical Oncology, The University of Hong Kong, Hong Kong, China
Dan Xie, e-mail: firstname.lastname@example.org
Keywords: non-small-cell lung carcinoma, CHD1L protein, metastasis, prognosis, gene amplification
Received: May 24, 2015 Accepted: August 14, 2015 Published: August 24, 2015
CHD1L (chromodomain helicase/ATPase DNA binding protein 1-like gene) has been demonstrated as an oncogene in hepatocellular carcinoma (HCC), however, the role of CHD1L in non-small-cell lung cancer (NSCLC) tumorigenesis hasn't been elucidated. In this study, the expression and amplification status of CHD1L were examined by immunohistochemistry and fluorescence in situ hybridization respectively in 248 surgically resected NSCLCs. The associations between CHD1L expression and clinicopathologic features and the prognostic value of CHD1L were analyzed. Overexpression and amplification of CHD1L was found in 42.1% and 17.7% of NSCLCs, respectively. The frequency of CHD1L overexpression (53.2% vs. 28.1%, P = 0.002) and amplification (25.2% vs. 8.2%, P = 0.020) in adenocarcinoma (ADC), was much higher than that in squamous cell carcinoma (SCC). CHD1L overexpression was associated closely with ascending pN status (P < 0.001), advanced clinical stage (P = 0.001) and tumor distant metastasis (P = 0.001) in ADCs, but not in SCCs. For the whole cohort and ADC patients, univariate survival analysis demonstrated a significant association of CHD1L overexpression with shortened survival; and in multivariate analysis, CHD1L overexpression was evaluated as a independent predictor for overall survival and distant metastasis free survival. These results suggested that overexpression of CHD1L is positively associated with tumor metastasis of lung ADC, and might serve as a novel prognostic biomarker and potential therapeutic target for lung ADC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.